Skip to main content

Blackstone-Panchshil Realty JV in early-stage talks for REIT IPO

If the plan fructifies, this would be the third REIT IPO in India backed by Blackstone, after Embassy Office Parks and Mindspace.

Blackstone, the largest owner of commercial real estate in India and Pune-based luxury property developer Panchshil Realty are evaluating a potential monetization of their joint venture assets via the real estate investment trust (REIT) route, sources with knowledge of the matter told Moneycontrol. If the proposed plan fructifies, it would be a hat-trick of REIT IPOs backed by Blackstone in India. Previously, the US private equity giant has launched the Embassy Office Parks REIT and the Mindspace REIT which it backs along with developer K Raheja Corp.

“These are very early days as structuring and reorganisation of the joint portfolio needs to be done to make it REIT ready, but preliminary discussions have begun for a listing of the commercial assets. There is no clarity yet on the issue size as they are mulling on the assets to be added to the REIT, “ said one of the individuals cited above.



“Panchshil Realty is one of the largest real estate developers in Pune with good assets in strategic locations. In all probability, most of the joint venture assets in Pune may be monetized but to ensure geographical diversification for investors, a few from Mumbai may also be added. This latest REIT offering is likely to be launched in 2021,” said a second individual.

Both the individuals spoke to Moneycontrol on the condition of anonymity. When contacted, Blackstone declined to comment. Moneycontrol is awaiting an email response from Panchshil Realty and its MD Atul Chordia and has sent reminders. This article will be updated as soon as we hear from the firm.

Established in 2002, Panchshil Realty has delivered over 23 million sq. ft. of real estate, with 20 million sq. ft. under development across multi-asset classes.  Its portfolio includes commercial, residential, hospitality , retail and f&b assets in Pune, Mumbai and South Delhi and its clients include the likes of Barclays, Citi, Dell, Deloitte, IBM, TCS, Hyundai, Bajaj Group and others. According to reports, Panchshil Realty and Blackstone jointly own prime office assets like Eon Free Zone

(India’s first notified SEZ in Pune’s Kharadi area ), First International Finance Centre, BKC, Mumbai and the iconic Indian Express Towers in South Mumbai.

The rise of the REIT regime

A real estate investment trust is a company that owns and operates income-producing properties or real estate. Modelled after mutual funds, REITs pool the capital of numerous investors and generate a steady income for their investors. REITs own many types of commercial real estate, ranging from office and apartment buildings to warehouses, hospitals, shopping centres and hotels.

In June 2020,  Blackstone raised around $300 million by selling some of its units in Embassy Office Parks Real Estate Investment Trust (REIT) to show a partial exit to its investors.  Later, on September 30, 2020, Moneycontrol reported that Blackstone's rival Canadian investment giant Brookfield Asset Management had filed documents with market regulator Sebi to raise around Rs 4000-Rs 4500 crore via REIT IPO.

According to experts tracking the segment, the low-interest rate regime, successful listing of earlier REITS, availability of top-notch sponsors, managers and portfolios, flight to safety (income yielding products) during the pandemic, the potential for stable income generation and strong occupancies in the office market are some of the key factors that have made REITs a popular instrument amongst both global and Indian investors.

Comments

Post a Comment

Popular posts from this blog

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...
Post a Comment
Read more

Brokerages place bets on Titan, see double-digit upside in the stock

Titan can get benefits from the strong market share in the jewellery and wrist watches segment, mainly driven by a wide range of product portfolio catering mainly to the premium and value-added designer jewellery segment. After three consecutive sessions of losses, shares of Titan Company rose over a percent in morning trade on BSE on September 23. The company was dealt a severe blow by COVID-19 as the pandemic triggered strict lockdowns completely battered the retail sector. In the calendar year so far, shares of this one of the largest, most efficient and profitable specialty retailer in India are 7 percent down. The company reported a net standalone loss of Rs 270 crore for the quarter ended June 2020 as the COVID-19 pandemic hit business. The loss was higher than a CNBC-TV18 poll estimate of Rs 175 crore. Standalone revenue during the quarter declined 62.3 percent year-on-year to Rs 1,862 crore compared to the corresponding period last fiscal. Light at the end ...
Post a Comment
Read more

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...
Post a Comment
Read more